Abstract
Lung disease is the main cause of morbidity and mortality in CF. The introduction of CFTR modulators has led to clinical benefits in CF patients. However, the extent to which these therapies reduce susceptibility to chronic lung infections remains to be elucidated. We aimed to evaluate the impact of ETI on CF airway microbiology after one year of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
